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Abstract The discovery of the causative gene for Huntington’s disease (HD) has promoted
numerous efforts to uncover cellular pathways that lower levels of mutant huntingtin protein (mHtt)
and potentially forestall the appearance of HD-related neurological defects. Using a cell-based
model of pathogenic huntingtin expression, we identified a class of compounds that protect cells
through selective inhibition of a lipid kinase, PIP4Kg. Pharmacological inhibition or knock-down of
PIP4Kg modulates the equilibrium between phosphatidylinositide (PI) species within the cell and
increases basal autophagy, reducing the total amount of mHtt protein in human patient fibroblasts
and aggregates in neurons. In two Drosophila models of Huntington’s disease, genetic knockdown
of PIP4K ameliorated neuronal dysfunction and degeneration as assessed using motor performance
and retinal degeneration assays respectively. Together, these results suggest that PIP4Kg is a
druggable target whose inhibition enhances productive autophagy and mHtt proteolysis, revealing
a useful pharmacological point of intervention for the treatment of Huntington’s disease, and
potentially for other neurodegenerative disorders.
DOI: https://doi.org/10.7554/eLife.29123.001
Introduction
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder with no curative or
preventative treatment options. The disease is caused by the expansion of a translated CAG trinucle-
otide repeat within exon 1 of the huntingtin gene (HTT), resulting in a mutant huntingtin (mHtt) pro-
tein with an abnormally long N-terminal tract of glutamine residues (Ross and Tabrizi, 2011).
Individuals with more than 36 to 39 repeats develop the disorder, and the length of the repeat cor-
relates with the age of disease onset (Walker, 2007). The poly-glutamine repeat expansion impacts
the physical (Kazantsev et al., 1999) and physiological (Hipp et al., 2012; Verhoef et al., 2002;
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Fernandez-Estevez et al., 2014) properties of the huntingtin protein, producing aggregates in
aged striatal neurons that eventually precipitate to form neuronal inclusion bodies (Miller et al.,
2010a). Accumulation of mHtt triggers a variety of insults that lead to striatal degeneration, how-
ever, the nature of the specific mHtt species, soluble, oligomeric or aggregate, that triggers neuro-
degeneration remains unclear (Arrasate et al., 2004; Lajoie and Snapp, 2010). In the last decade, a
number of potential therapeutic avenues have been proposed to prevent or attenuate the neurode-
generation induced by mHtt, including examining the effects of mHtt-induced oxidative stress
(Wyttenbach et al., 2002; Giuliano et al., 2003; Lu et al., 2014), huntingtin posttranscriptional
modifications (Steffan et al., 2004; Greiner and Yang, 2011; Bhat et al., 2014; Pavese et al.,
2006), microglia activation (Gusella and MacDonald, 2009), a systematic exploration of coding
(Gusella and MacDonald, 2009) and non-coding (Zhang and Friedlander, 2011) DNA, and autoph-
agy (Sarkar et al., 2009; Williams et al., 2008). However, it has been difficult to identify druggable
targets that reduce disease progression (Bard et al., 2014). In addition to targeting mHtt-induced
downstream pathogenic events, an attractive alternative for developing HD therapies is reducing the
levels of mHtt protein, thus addressing pathogenesis at its root. The therapeutic potential of this
approach is supported by observations in animal and cellular models of HD (Sarkar et al., 2009;
King et al., 2008; Singh et al., 2014; Giorgini, 2011; Yamamoto et al., 2000; Lin and Qin, 2013;
Sarkar et al., 2007). Here we present PIP4Kg as a novel therapeutic target for HD. PIP4Kg [Phospha-
tidylinositol-5-phosphate 4-kinase, type II g ] is a lipid kinase expressed by the PIP4K2C gene. The
protein is predominantly localized in several tissues, including the brain (Sasaki et al., 2009;
Rameh et al., 1997; Clarke et al., 2008; Clarke et al., 2009). Enzymatically, PIP4Kg phosphorylates
phosphatidylinositol-5-phosphate [PI5P] to produce phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2]
(Lietha, 2011). The biological function of PIP4Kg is not completely understood, although recent
reports suggest a role in the modulation of vesicle trafficking (Clarke et al., 2008), and mTOR sig-
naling (Mackey et al., 2014). Recently we presented the first selective inhibitor of PIP4Kg
(Clarke et al., 2015). Here we introduce an additional chemotype with striking cell-based activity
which prompted us to explore the utility of inhibiting PIP4Kg in the context of pathologic mHtt
expression. We show that inhibiting PIP4Kg activity modulates productive autophagy, reduces mHtt
protein levels in patient fibroblasts, and clears mHtt aggregates in neuronal cell models. Moreover,
we show that inhibition of PIP4Kg rescues mHtt-induced neurodegeneration in two Drosophila HD
models.
Results
Identification of novel PIP4Kg inhibitors
NCT-504 (Figure 1A) is an analogue obtained upon medicinal chemistry optimization of a series of
5-phenylthieno[2,3-d]pyrimidine compounds identified in a high-throughput phenotypic screen
(Titus, 2010). Expression of GFP-Htt(exon1)-Q103 in PC12 cells produces detergent-resistant GFP-
labeled aggregates (Titus et al., 2012). NCT-504 caused a robust reduction of GFP-Htt(exon1)-
Q103 levels, as measured by lowered GFP signal (Figure 1B and C). NCT-504 treatment also
decreased huntingtin aggregates in HEK293T cells transiently transfected with GFP-Htt(exon1)-Q74
(Figure 1—figure supplement 1). As thienopyrimidines have been associated with kinase activity
(Elrazaz et al., 2015) we profiled NCT-504 against a panel of 442 human kinases http://www.discov-
erx.com/technologies-platforms/competitive-binding-technology/kinomescan-technology-platform.
Using a cutoff of >65% inhibition at 10 mM, NCT-504 was active against only a single kinase, PIP4Kg
(Table 1). Similarly, another analogue from the same thienopyrimidine series, ML168 (Titus, 2010),
had activity against six kinases in the same panel, but was most potent against PIP4Kg.
To better characterize the biochemical action of NCT-504, we evaluated its inhibitory activity in
several in vitro kinase assays. NCT-504 modulated the activity of PIP4Kg in the DiscoverX binding
assay (https://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/
kinomescan) with a Kd = 354 nM (Figure 1D). Using a reconstituted assay of phosphorylation of the
PI5P substrate by full length PIP4Kg, NCT-504 inhibited enzyme activity with an IC50 of 15.8 mM
(Figure 1E). Notably, in the absence of PI5P substrate, the compound did not impair the intrinsic
ATP-hydrolytic activity of PIP4Kg (Figure 1F), suggesting that NCT-504 is an allosteric inhibitor of
this kinase. This may account for the differences in potency observed in the enzymatic assay vs the
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Figure 1. Identification of NCT-504 and its inhibition of PIP4Kg. (A) Structure of NCT-504. (B) NCT-504 treatment reduces Htt(exon1)-Q103 in PC12 cells.
Cells with stable expression of ecdysone-inducible GFP-Htt(exon1)-Q103 (green), induced for 24 hr, and treated with DMSO (top panels) or 23 mM NCT-
504 (bottom). Cells stained with DAPI (blue). Scale Bar = 50 mm. (C) Concentration-response curve of NCT-504 inhibition of cellular accumulation of
GFP-Htt(exon1)-Q103 in PC12 cells. (D) NCT-504 inhibition of PIP4Kg binding to an immobilized proprietary active site ligand (DiscoverX KINOMEscan
https://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan). (E) NCT-504 exhibits dose-dependent
Figure 1 continued on next page
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DiscoverX binding assay. Similar differences in potency between these two assays have also been
observed for allosteric modulators of other kinases (Rudolf et al., 2014; Smyth and Collins, 2009).
NCT-504 function as an allosteric inhibitor may also explain why NCT-504 is exquisitely selective in
the kinase profiling assay. In isolated enzyme assays against other PIP4K isoforms, 50 mM NCT-504
did not inhibit PIP4Kbeta or PIP4Kalpha (IC50 between 50 mM and 100 mM) (Figure 1—figure sup-
plement 2). We also characterized the compound using an alternate PIP4Kg+ functional assay, which
employs PIP4Kg with a mutated G-loop and two additional mutations (described as PI5P4Kg G3 +
AB in [Clarke and Irvine, 2013]) to increase the low intrinsic ATP turnover of the kinase in the pres-
ence of PI5P (Clarke and Irvine, 2013). NCT-504 was largely inactive against PIP4Kg+ with a
potency >500 mM (Figure 1—figure supplement 3).
PIP4Kg inhibition modulates cellular phosphatidylinositide levels in
complex ways
Cellular inhibition of PIP4Ks should impair the production of PI(4,5)P2 from PI5P, resulting in an ele-
vation of PI5P cellular levels as previously described in the Drosophila mutant (Gupta et al., 2013).
Note that other PI levels were not tested in the dPI4PK Drosophila mutant. We hypothesized that
elevation of PI5P might further impact the equilibrium between various PI species (Lietha, 2011;
Emerling et al., 2014; Balla, 2013). To test this hypothesis, we exposed wild type mouse embryonic
fibroblasts to nontoxic concentrations of NCT-504 (10 mM) for 12 hr, and then evaluated the levels
of PI by HPLC (Figure 2; toxicity assay in Figure 2—figure supplement 1). As expected, exposure
to NCT-504 elevated cellular levels of PI5P (Figure 2D). Surprisingly, NCT-504 also robustly
increased PI(3,5)P2 levels, and to a lesser extent increased levels of PI3P (Figure 2B and E). We did
not observe an effect on PI(4,5)P2 levels (Figure 2F), which is consistent with other reports indicating
that the cellular levels of this lipid are mostly generated from PI4P via type I PI4P 5-kinases
Figure 1 continued
inhibition of phosphorylation of PI4P by full length isolated PIP4Kg. (F) The intrinsic ATPase specific activity of full length isolated PIP4Kg in the absence
of PI5P substrate as a function of NCT-504 concentration is the same in the presence (blue) or in the absence (purple) of NCT-504.
DOI: https://doi.org/10.7554/eLife.29123.002
The following figure supplements are available for figure 1:
Figure supplement 1. NCT-504 suppresses the accumulation of HTT-exon1 aggregates.
DOI: https://doi.org/10.7554/eLife.29123.003
Figure supplement 2. NCT-504 does not inhibit PIP4Kbeta and weakly inhibits PIP4Kalpha phosphorylation of PI5P.
DOI: https://doi.org/10.7554/eLife.29123.004
Figure supplement 3. A PIP4Kg+ G-loop mutant is resistant to inhibition by NCT-504, consistent with NCT-504 functioning as an allosteric inhibitor.
DOI: https://doi.org/10.7554/eLife.29123.005
Table 1. Kinase profiling results for NCT-504 and ML168.
Percent activity remaining at 10 mM exposure of NCT-504 and ML168 in KINOMEscan kinase panel/
profiling http://www.discoverx.com/technologies-platforms/competitive-binding-technology/kinomes-
can-technology-platform. Top 3 NCT-504 inhibited kinases are reported as single replicate data. Full
data set is provided in Table 1 – source data file. PIP4K2g potencies were confirmed in triplicate con-
centration-response testing (Figure 1D).
Kinase ML168 NCT-504
PIP4K2C 23 4.9
RSK1(Kin.Dom.2-C-terminal) 20 40
GAK 10 42
% Control Legend
0%  x < 10%
10%  x < 35%
35%  x
DOI: https://doi.org/10.7554/eLife.29123.006
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Figure 2. Pharmacologic and genetic inhibition of PIP4Kg elevates the levels of PI(3,5)P2, PI3P and PI5P in MEFs. (A–F) Pharmacologic (NCT-504 10 mM,
12 hr) and genetic (shRNA) inhibition of PIP4Kg leads to increased levels of PI5P (D), PI(3,5)P2 (E) and PI3P (B), with no significant change in the levels of
phosphatidylinositol (A), PI4P (C) or PI(4,5)P2 (F). However, there was a modest reduction in PI4P. Note in Figure 2—figure supplement 2, this small
change was statically significant. Measurements were performed in MEF cells incubated with 3H-inositol labeled media for 48 hr. Statistical significance
was analyzed using paired one tailed student t-test (n = 3), *p<0.05, **p<0.01. (G) Anti-PIP4Kg western blot showing the effective silencing of the
enzyme using shRNA. (GAPDH used as loading control).
DOI: https://doi.org/10.7554/eLife.29123.007
The following figure supplements are available for figure 2:
Figure supplement 1. NCT-504 treatment does not affect cell viability in MEFs.
DOI: https://doi.org/10.7554/eLife.29123.008
Figure supplement 2. Time course of phosphatidylinositol lipid changes upon NCT-504 treatment (10 mM) in MEFs.
DOI: https://doi.org/10.7554/eLife.29123.009
Figure supplement 3. Modulation of the levels of phosphatidylinositol lipids by NCT-504 in unaffected human fibroblasts.
DOI: https://doi.org/10.7554/eLife.29123.010
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(Lietha, 2011). Kinetic measurement of PI levels showed that NCT-504 causes an increase in PI5P, PI
(3,5)P2 and PI3P levels along with a decrease in PI4P, progressively over 12 hr (Figure 2—figure
supplement 2). These statistically significant changes were not observed at 30 or 120 min suggest-
ing that direct inhibition of PIP4Kg eventually impacts other lipid kinases and phosphatases. More-
over treatment of unaffected human fibroblasts with NCT-504 elevated these three lipids in a dose
dependent manner (Figure 2—figure supplement 3). Further evidence that the changes in PI levels
are due to the specific inhibition of PIP4Kg , is the finding that shRNA-mediated silencing of PIP4Kg
resulted in a similar PI profile to that observed with NCT-504 inhibition, namely an elevation of PI5P,
PI(3,5)P2 and PI3P (Figure 2B,D and E). Note that during shRNA-mediated silencing of PIP4Kg tran-
scripts, PIP4Kg protein was no longer detected (Figure 2G).
PIP4Kg inhibition stimulates productive autophagy
Numerous studies have shown that mHtt upregulates autophagy, but impairs incorporation of client
proteins into autophagosomes (Cortes and La Spada, 2014; Ochaba et al., 2014; Martin et al.,
2015; Martinez-Vicente et al., 2010; Tsvetkov et al., 2013). Importantly, a number of autophagy
modulators have been described that reduce mHtt aggregates (Sarkar et al., 2009; Roscic et al.,
2011; Zhang et al., 2007; Renna et al., 2010). That NCT-504 elevates the levels of three PI species
implicated as positive regulators of autophagy suggests that the observed reduction in HTT-exon1-
polyQ aggregates observed with NCT-504 treatment may occur due to upregulation of autophagy.
Autophagy can be monitored by following the fate of microtubule-associated protein 1 light chain
3B (LC3-I). During autophagosome formation LC3-I gets conjugated to phosphatidylethanolamine to
form LC3-II, which is degraded upon autophagosome-lysosome fusion (Tanida et al., 2008). We
tested and found that a two hour incubation of HEK293T cells with 5 or 10 mM NCT-504 did not sig-
nificantly increase LC3-II levels (Figure 3A and B). However, LC3-II levels depend on the rate of
autophagosome formation, the rate of autophagosome-lysosome fusion, and on the rate of LC3-II
degradation in mature autolysomes. Bafilomycin A1 inhibits the lysosomal v-ATPase, prevents auto-
phagosome-lysosome fusion, and thus prevents autophagy-mediated degradation of LC3-II. Com-
parison of cells treated with and without bafilomycin A1 is a common method to monitor the rate of
autophagosome formation within the cell independent of later steps (Barth et al., 2010). Bafilomy-
cin A1 treatment for 2 or 6 hr elevated the total amount of LC3-II (Figure 3A and C). Importantly,
treating cells with 10 mM NCT-504 and 100 nM bafilomycin A1 for two hours and six hours resulted
in a 38% and 51% increase in LC3-II levels respectively compared with bafilomycin A1 treatment
alone, which indicates that NCT-504 induces autophagosome formation. Similarly, treating cells with
5 mM NCT-504 and bafilomycin A1 for two and six hours resulted in a 30% and 46% increase in LC3-
II levels respectively. Importantly, an elevation in LC3-II levels by NCT-504 in the presence of bafilo-
mycin A1 but not in the absence of bafilomycin A1, suggests that NCT-504 elevates both the induc-
tion of autophagy as well as the rate of turnover of autophagic cargo (autophagy flux). To further
evaluate the effects of NCT-504 on autophagosome formation and autophagy flux, we used a 293A
cell line stably expressing a GFP-mCherry-LC3 reporter (Figure 3—figure supplement 1). This dou-
ble tagged LC3 is commonly used to distinguish between autolysosomes and autophagosomes or
phagophores (Hundeshagen et al., 2011; Kimura et al., 2007). Phagophore and autophagosome
membranes conjugated with GFP-mCherry-LC3 are positive for both GFP- and mCherry-fluores-
cence. Upon generation of mature autolysosomes via fusion of autophagosomes with lysosomes, the
GFP fluorescence from the internalized GFP-mCherry-LC3 is quenched in the acidic lysosomes;
whereas mCherry fluorescence is insensitive to acidic pH and remains detectable. Thus, membrane
structures positive for mCherry fluorescence, but not GFP fluorescence are autolysosomes. We
determined the dose and time response of NCT-504 on autophagosomes and autolysosomes using
GFP-mCherry-LC3; bafilomycin and torin-1 were used as controls (Figure 3—figure supplement 1).
As previously reported, bafilomycin treatment resulted in an increase in autophagosomes because
the subsequent formation of autolysosomes is blocked. In addition, as previously reported, torin
treatment elevated both the number of autophagosomes and autolysosomes, because inhibition of
mTORC1 causes an increase in the induction of autophagy as well as an increase in autophagic flux.
In contrast, NCT-504 treatment caused a robust increase in the formation of autolysosomes with
only a modest elevation in autophagosomes, which indicates that NCT-504 increases autophagic
flux, with only a modest increase in autophagy initiation.
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Figure 3. Inhibition of PIP4Kg increases autophagy flux. (A) Representative Western blots showing the levels of LC3-I, LC3-II and Tubulin (loading
control) in HEK293T cells treated with either 5 or 10 mM NCT-504 or DMSO (control) for two or six hours in the presence or absence of 100 nM
bafilomycin. (B–C) Quantification of LC3-II levels detected by western blot normalized to a-tubulin (loading control). Changes in LC3-II with drug
treatment alone is presented relative to levels in the DMSO control cell lysates (B) and changes in LC3-II with drug treatment plus bafilomycin is
presented relative to DMSO plus bafilomycin (C). Statistical significance was quantified from three independent experiments using Dunnett’s multiple
comparisons test, *p<0.05, **p<0.01, ***p<0.005.
DOI: https://doi.org/10.7554/eLife.29123.011
The following figure supplements are available for figure 3:
Figure supplement 1. NCT-504 increases autophagy flux and decreases huntingtin protein in 293A cells.
DOI: https://doi.org/10.7554/eLife.29123.012
Figure supplement 2. PIP4Kg inhibition increases the rate of autophagic flux in cortical neurons.
Figure 3 continued on next page
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While mechanisms of autophagy are highly similar in all cells, neurons exhibit some key differen-
ces. For example starvation does not upregulate autophagy (Mizushima et al., 2004). In addition,
autophagy is spatially regulated (Maday and Holzbaur, 2014). Thus, we tested whether NCT-504
impacts autophagy in neurons. We tested several doses and time points (up to 72 hr after treatment)
and measured autophagy flux in DIV4 rat primary cortical neurons transfected with Dendra2-LC3, a
photoconvertable reporter (Figure 3—figure supplement 2). Dendra2 has excitation-emission max-
ima that are similar to GFP. However, exposure to intense blue light raise these maxima, and thus
red light is emitted. Since the photoconversion reaction is irreversible, and LC3 is both a marker of
autophagy as well as a substrate, the disappearance of red Dendra2-LC3 over time can be used to
assess autophagy flux in a noninvasive manner (Gupta et al., 2017; Barmada et al., 2014). As a pos-
itive control for an increase in autophagic flux in neurons, we co-expressed Beclin-1, a positive regu-
lator of autophagy that increases autophagy activity when overexpressed (Kang et al., 2011).
Importantly, treatment of rat primary cortical neurons expressing Dendra2-LC3 with either 500 nM
or 1 mM NCT-504 enhanced the rate of Dendra2-LC3 turnover. Thus, NCT-504 stimulates autophagy
flux in primary rodent cortical neurons in a statistically significant manner up to 72 hr following
treatment.
That NCT-504-induced changes in autophagic flux were dose dependent, led us to test whether
the resultant increase in autophagy correlated with changes in Htt levels. We found that 293A cells
display a high content of wt Htt, which enabled us to use an anti-Htt FRET assay (Cui et al., 2014).
Using this assay, we found that NCT 504 treatment resulted in a dose dependent decrease of Htt
protein levels at levels that did not impact cell viability (Figure 3—figure supplement 1C and D).
To further test whether NCT-504 reduces mHtt aggregates via increasing autophagic flux, we
tested the ability of NCT-504 to lower GFP-Htt(exon1)-Q74 aggregates in a cells with a defect in
macroautophagy. We found that while NCT-504 lowered the levels of GFP-Htt(exon1)-Q74 aggre-
gates in Atg7+/+ MEF, it failed to lower aggregates in Atg7-/- MEF; Atg7 is essential for autophago-
some formation and its loss inhibits the autophagy pathway (Figure 3—figure supplement 3).
That PI3P is a critical regulator of autophagy (Shibutani and Yoshimori, 2014), and that PI5P and
PI(3,5)P2 have also been implicated in the autophagy process (Vicinanza et al., 2015;
Hasegawa et al., 2017), suggests that upregulation of one or more of these lipids is the driver
behind the increase in autophagic flux. Importantly, NCT-504 treatment contrasts with the action of
other autophagy modulators such as mTORC1 inhibitors which produce stable increases in LC3-II
(Boland et al., 2008), accelerating the initiation of autophagy but not necessarily later steps which
require mTOR reactivation (Munson and Ganley, 2015).
Blocking PIP4Kg activity reduces levels of full-length mutant huntingtin
protein and levels of Htt(exon1)-polyQ aggregates
To test whether PIP4Kg inhibition lowers full-length mHtt protein, we used immunoblots to deter-
mine the effect of NCT-504 on mHtt levels in patient fibroblasts and immortalized striatal neurons
from a knock-in HD mouse model. Notably, treatment with 5 mM NCT-504 for 12 hr, conditions that
did not affect cell viability (Figure 4—figure supplement 1), significantly reduced mHtt levels in
fibroblasts from two different HD patients HD(Q68) or HD(Q45) (Figure 4A and C). To further test
whether the reduction of mHtt levels was due to selective modulation of PIP4Kg, we individually
silenced PIP4K2A, PIP4K2B and PIP4K2C RNA in the HD(Q68) patient fibroblast cell line. Only silenc-
ing of PIP4K2C exhibited an appreciable and robust reduction of huntingtin protein levels
(Figure 4B). Note that silencing of PIP4K2A, PIP4K2B and PIP4K2C was effective and specific for
each isoform (Figure 4—figure supplement 2). We also tested the effect of NCT-504 on the levels
of mutant full-length huntingtin protein in immortalized striatal neurons. We treated a striatal cell
line from a knock-in HD mouse (STHdhQ111) (Trettel et al., 2000), with 5 mM NCT-504 for 12 hr
and observed a 40% decrease in mHtt levels (Figure 4D).
Figure 3 continued
DOI: https://doi.org/10.7554/eLife.29123.013
Figure supplement 3. Lowering mHtt aggregates via NCT-504 requires macroautophagy: (A-B) Atg7+/+ and Atg7-/- cells were transfected with GFP-
Htt(exon1)-Q74.
DOI: https://doi.org/10.7554/eLife.29123.014
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Figure 4. Chemical inhibition of PIP4Kg or knock-down of the corresponding mRNA, PIP4K2C, lowers mHtt protein levels in cells from HD patients and
HD knock-in mice. (A) Reduction of mHtt protein levels in an HD patient fibroblast cell line (Q68) following exposure for 12 hr to NCT-504 (5 mM) (B)
mHtt protein levels in patient fibroblast cell line (Q68) were analyzed following siRNA-mediated silencing of PIP4K2A, PIP4K2B and PIP4K2C genes.
Note that only PIP4K2C knockdown lowers mHtt levels. Control experiments showing silencing specificity on PIP4K protein levels are in Figure 4—
figure supplement 3. (C) Reduction of mHtt protein levels in an HD patient fibroblast cell line (Q45) following exposure to NCT-504 (5 mM). (D)
Reduction of mHtt protein levels in immortalized striatal cells from knock-in HD mice (STHdhQ111) treated for 12 hr with NCT-504 (5 mM).
DOI: https://doi.org/10.7554/eLife.29123.015
The following figure supplements are available for figure 4:
Figure supplement 1. Cell viability of HD patient fibroblasts (Q45) exposed to the indicated doses of NCT-504 for 12 hr as per the CellTiter-Glo
Promega assay.
DOI: https://doi.org/10.7554/eLife.29123.016
Figure supplement 2. Knock-down efficiency and specificity of small interfering RNA in HD patient fibroblasts (Q45).
DOI: https://doi.org/10.7554/eLife.29123.017
Figure supplement 3. Experimental details and controls for mouse primary cortical neurons transduced with Htt(exon1)-Q72.
DOI: https://doi.org/10.7554/eLife.29123.018
Figure supplement 4. Reduction of Htt protein levels or aggregate by inhibition of PIP4Kg or PIP4K2C knockdown.
DOI: https://doi.org/10.7554/eLife.29123.019
Figure supplement 5. Effect of PIP4K2C knockdown on mHtt aggregates in N2a transfected cells.
DOI: https://doi.org/10.7554/eLife.29123.020
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To examine the impact of NCT-504 on the levels of huntingtin-related aggregates in neurons, we
evaluated the effect of NCT-504 in wild-type mouse primary cortical neurons transfected with Htt
(exon1)-Q74. We tested and found that concentrations of NCT-504 of 5 mM or lower did not impact
the viability of cortical neurons (Figure 4—figure supplement 3). Importantly, 2.5 or 5 mM NCT-504
lowered the levels of Htt(exon1)-Q74 in primary cortical neurons (Figure 4—figure supplement 4A).
Moreover, depletion of PIP4Kg in cortical neurons via PIP4K2C-shRNA treatment also led to a
decrease in Htt(exon1)-Q74 levels and Htt(exon1)-Q74 aggregates (Figure 4—figure supplement
4B). Furthermore, NCT-504 treatment and PIP4K2C silencing each reduced Htt(exon1)-polyQ aggre-
gates in neuroblastoma N2a cells transfected with Htt(exon1)-polyQ mutants (Figure 4—figure sup-
plement 5).
Collectively, these studies show that NCT-504, a PIP4Kg kinase inhibitor, at non-toxic concentra-
tions, reduced full length huntingtin protein in patient fibroblasts, in immortalized striatal neurons
from STHdhQ111 mutant mice and in HEK293T cells. Moreover, NCT-504 reduced the levels of Htt
(exon1)-polyQ aggregates in primary cultured neurons and several cell lines. Similarly, specific silenc-
ing of the PIP4K2C gene led to reduction in the levels of full-length huntingtin and HTT-exon1-polyQ
protein and aggregates. The lowering of huntingtin and Htt(exon1)-polyQ by NCT-504 was concen-
tration dependent. Moreover, the levels of NCT-504 that reduced these mutant proteins increased
autophagic flux. Importantly, NCT-504 did not lower Htt(exon1)-polyQ protein in Atg7-/- MEF, but
lowered Htt(exon1)-polyQ protein in the corresponding Atg7+/+ MEF. Together these studies indi-
cate that inhibition of PIP4Kg lowers mutant Htt, via an increase in autophagic flux.
Phenotypic effects of PIP4K modulation in Drosophila models of
Huntington’s disease
Unlike mammals, which have three PIP type II enzymes (PIP4Kalpha, PIP4Kbeta and PIP4Kg ), there is
only one type II PIP kinase homologue in Drosophila (dPIPK4 also called CG17471) (Mackey et al.,
2014). We used a well-established HD Drosophila model (Kaltenbach et al., 2007; Branco et al.,
2008; Miller et al., 2010b; Lu et al., 2013; Yao et al., 2015) to evaluate the impact of modulating
the dPIP4K gene on the pathogenesis induced by mHtt expression. The GAL4/UAS system
(Elliott and Brand, 2008) is used to drive expression of an N-terminal human 128Q mHtt
(HttN231Q128) fragment to the cell type of choice. First, we assessed the Drosophila retina and its
photoreceptor cells. Control HD model animals with wild-type activity of dPIP4K show prominent
mHtt-induced photoreceptor degeneration. This phenotype is ameliorated by reducing dPIP4K activ-
ity with either one of two different shRNAs (Figure 5A). In a second set of experiments we tested
the potential of dPIP4K to modulate mHtt pathogenesis using a behavioral readout. Neuronal-spe-
cific expression of HttN231Q128 leads to a late-onset motor impairment that can be quantified in a
climbing assay. This phenotype was also ameliorated by reducing the activity of dPIP4K using a pre-
viously described (Gupta et al., 2013) classical loss-of-function mutant allele in heterozygosis and a
kinase dead allele (Figure 5B). Additionally, we also evaluated these approaches (loss-of-function by
a heterozygous mutant allele and kinase dead allele) in animals expressing full length Htt carrying a
200 polyQ expansion in exon1. Notably, we observed a mitigation of the motor performance decline
in this full-length HD model. Decreasing the levels of PIP4K with the same alleles in the absence of
mHtt did not affect motor performance when compared to controls (Figure 5—figure supplement
1). Thus, reducing the activity of dPIP4K using different genetic approaches mitigates mHtt patho-
genesis in three different assays.
Discussion
Our unbiased screen for compounds that protect cells against a pathogenic huntingtin fragment
reveal PIP4Kg as a potential target for Huntington disease. The compounds identified led to the
development of NCT-504, a selective fully efficacious inhibitor of PIP4Kg. NCT-504 treatment or
knock-down of PIP4Kg lowers huntingtin fragments Htt(exon1)-polyQ in multiple cell types including
cortical and striatal neurons, and lowers full-length mutant huntingtin in patient fibroblasts and
mouse striatal neurons. Moreover, genetic targeting of PIP4K in two Drosophila models of HD, miti-
gated associated HD phenotypes. Importantly, we observed two major changes in cells following
PIP4Kg inhibition, an increase in autophagic flux, and an increase in the levels of three
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Figure 5. Reduced dPIP4K gene activity ameliorates photoreceptor degeneration and behavioral impairments in a Drosophila HD model. (A) Sections
through the Drosophila retina showing loss of photoreceptor cells and retinal tissue in animals expressing N-terminal mHtt (HTTNT231Q128) in the eye
(compare no modifier with negative control panels). The photoreceptor and retinal loss phenotype is ameliorated in HttNT231Q128 animals that also
express anyone of two shRNAs targeting dPIP4K. (B) Chart shows motor performance (%) as a function of age in negative controls (dPIP4K+/+, blue
dotted line), Drosophila expressing N-terminal mHtt in the CNS (HTTNT231Q128/dPIP4K+/+, black line) or animals expressing N-terminal mHtt in the
CNS together with a dPIP4K heterozygous loss of function (HTTNT231Q128/dPIP4K+/-, red continuous line) or a dPIP4K kinase dead isoform
(HTTNT231Q128/dPIP4K+/DN, green continuous line). Notice the amelioration of mHtt-induced deficits upon decreasing the activity of dPIP4K. (C)
Chart shows motor performance (%) and climbing speed as a function of age in negative controls (dPIP4K+/+, blue dotted line), Drosophila expressing
full length mHtt in the CNS (HTT-FLQ200/dPIP4K+/+, black line) or animals expressing FL mHtt in the CNS together with a dPIP4K heterozygous loss of
function (HTT-FL200/dPIP4K+/-, red continuous line) or a dPIP4K kinase dead isoform (HTT-FL200/dPIP4K+/DN, green continuous line). Note
amelioration of neural HttNT231Q128-induced motor deficits by decreasing the activity of dPIP4K. Genotypes in A: Negative control: GMR-GAL4/+;
dPIP4K+/+. No modifier: GMR-GAL4/+; UAS:HTTNT231Q128/+; dPIP4K+/+. PIP4K2 sh1/sh2: GMR-GAL4/+; UAS:HTTNT231Q128/UAS:dPIP4Ksh-1 or
sh-2. Genotypes in B: Negative control: elavc155GAL4/+; dPIP4K+/+.HTT231Q128: elavc155GAL4/+; UAS:HttNT231Q128/+; dPIP4K+/+. HTT231Q128/
Figure 5 continued on next page
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phosphoinositide signaling lipids. It is tempting to speculate that the changes in PI upregulate auto-
phagic flux, and thereby lower mHtt levels.
Little is currently known about cellular roles of PIP4Kg . However, in line with our current findings,
previous studies observed that knock-down of PIP4Kg resulted in an increase in autophagy
(Mackey et al., 2014; Vicinanza et al., 2015), and a reduction of EGFP-HttQ74 aggregates in MEFs
that was dependent on the presence of the autophagy gene, ATG7 (Mackey et al., 2014;
Vicinanza et al., 2015).
While increasing the proteolysis of pathogenic huntingtin protein via the upregulation of autoph-
agy is an attractive therapeutic approach for HD (Lin and Qin, 2013; Sarkar et al., 2007), there are
potential challenges. Mutant huntingtin itself may alter autophagy. Wild-type huntingtin may be an
adaptor for selected autophagic cargoes including itself (Martinez-Vicente et al., 2010). Consistent
with this hypothesis, mutant huntingtin impairs the loading of ubiquitinated-tagged proteins into
autophagosomes (Martinez-Vicente et al., 2010), and circumvents its own clearance (Martin et al.,
2015). Moreover, mutant huntingtin sequesters diverse proteins required for key cellular processes
(Kim et al., 2016), including mTOR, which plays key roles in the regulation of autophagy
(Tsvetkov et al., 2013; Peterse´n A et al., 2001; Ravikumar et al., 2004; Pryor et al., 2014;
Ashkenazi et al., 2017; Caviston et al., 2007; Wong and Holzbaur, 2014). In addition, the PI bind-
ing autophagy adaptor protein ALFY which plays a fundamental role in degrading mutant huntingtin
is down-regulated in HD (Martin et al., 2015; Filimonenko et al., 2010). In contrast with these find-
ings, there are studies that indicate that autophagy is not impaired in HD, and have revealed an ele-
vation of autophagy flux in HD cells (Peterse´n A et al., 2001; Kegel et al., 2000). Despite possible
mutant huntingtin-dependent changes on autophagy, upregulation of autophagy remains a viable
approach for lowering levels of mutant huntintin and aggregates (Lin and Qin, 2013; Sarkar et al.,
2007). Note that caloric restriction also raises the basal level of autophagy, leading to improvements
in HD models (Duan et al., 2003) and increasing axonal autophagosome transport (Ikenaka et al.,
2013), although it is less clear how to translate this observation into clinical practice.
One common approach to induce autophagy is via inhibition of the major metabolic kinase
mTORC1. Indeed, rapamycin, an inhibitor of mTORC1 also reduces mHtt protein levels
(Sarkar et al., 2009). However, while PIP4Kg likely impacts mTORC1 activity, it is not yet clear
whether PIP4Kg inhibition results in mTORC1 inhibition or activation. One study showed that knock-
down of PIP4K2C inhibits mTORC1 (Mackey et al., 2014). However, in PIP4K2C homozygous knock-
out mice, mTORC1 is elevated (Shim et al., 2016). Thus, the precise link between PIP4Kg and
mTORC1 is not clear. Importantly, our data suggest that PIP4Kg upregulation of autophagy has
some differences with upregulation of autophagy via mTORC1 inhibition. While inhibition of mTOR
via torin treatment exhibited a large increase in both autophagosome formation and autophagy flux,
inhibition of PIP4Kg had only a modest impact on autophagosome formation, but had a large
increase in autophagic flux (Figure 3—figure supplement 1). Thus, elucidation of the mechanism
whereby PIP4Kg inhibition increases autophagic flux remains to be fully determined.
It is likely that inhibition of PIP4Kg increases autophagic flux at least in part via the resulting
impact on the levels of selected phosphoinositide lipids. PIP4Kg is predicted to convert PI5P to PI
(4,5)P2. However, it was not known which cellular pools of PI5P are substrates for PIP4Kg. Using
NCT-504 we found no significant change in PI5P levels or other PI lipids following up to two hours of
inhibition of PIP4Kg. This contrasts with other lipid kinases such as PIKfyve, where direct inhibition
results in an acute loss of PI(3,5)P2 which can be observed within 5 min (Zolov et al., 2012;
Figure 5 continued
PIP4K2LOF: elavc155GAL4/+; UAS:HttNT231Q128/+; dPIP4K29/+ and HTT231Q128/PIP4K2DN: elavc155GAL4/+; UAS:HttNT231Q128/UAS:dPIP4K29
[D271K].. Genotypes in C: Negative control: elavc155GAL4/+; dPIP4K+/+. HTT-FLQ200: elavc155GAL4/+; UAS:HttFLQ200/+; dPIP4K+/+. HTT-FLQ200/
PIP4K2LOF: elavc155GAL4/+; UAS:UAS:HttFLQ200/+; dPIP4K29/+ and HTT-FLQ200/PIP4K2DN: elavc155GAL4/+; UAS:UAS:HttFLQ200/UAS:dPIP4K29
[D271K]. elavc155GAL4 drives expression of mHtt to all neurons but not other cell types. Means between points at each age were analyzed by ANOVA
followed by Dunnet’s post hoc test. Error bars indicate the s.e.m. *p<0.05.
DOI: https://doi.org/10.7554/eLife.29123.021
The following figure supplement is available for figure 5:
Figure supplement 1. Reduced dPIP4K gene activity in wild type Drosophila does not impact motility.
DOI: https://doi.org/10.7554/eLife.29123.022
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McCartney et al., 2014). The long delay prior to changes in PI5P following PIP4Kg inhibition sug-
gests that PIP4Kg is not in contact with most of the cellular PI5P, or is only active under specific con-
ditions. However, after 12 hr treatment with NCT-504, there was a 1.6 fold elevation of PI5P. The
fact that this change occurred well after 2 hr of inhibition, suggests that it might not be directly due
to an accumulation of the PI5P substrate normally used by PIP4Kg . Indeed, at 12 hr PI(3,5)P2 levels
were also elevated at 2-fold, which was even higher than the fold elevation in PI5P. This raises the
possibility that long-term inhibition of PIP4Kg indirectly results in the activation of PIKfyve. This acti-
vation of PIKfyve may account for the increase in PI5P as well as PI(3,5)P2 (Zolov et al., 2012;
McCartney et al., 2014; Sbrissa et al., 2012). In addition, at 12 hr PI3P levels increased 1.3 fold,
suggesting that VPS34 may be indirectly activated as well.
The elevation of PI3P, PI(3,5)P2 and/or PI5P likely contribute to the elevation in autophagic flux.
PI3P has well characterized roles in autophagy, and acts in initiation of phagophore formation
(Shibutani and Yoshimori, 2014) as well as in later steps of autophagosome maturation
(Carlsson and Simonsen, 2015), including autophagosome-lysosome fusion (Ikonomov et al., 2006)
and lysosome reformation (Rong et al., 2012; Yu et al., 2010). In some conditions, PI5P can induce
autophagy independent of PI3P (Vicinanza et al., 2015). In contrast, PI(3,5)P2 functions at a late
step in autophagy (Ikonomov et al., 2006; de Lartigue et al., 2009; Jin et al., 2008; Jin et al.,
2014; Ikonomov et al., 2001; Martin et al., 2013; Rusten et al., 2007; Sano et al., 2016). These
late functions, may contribute to the observed increase in autophagic flux. In addition to these
changes the statistically significant decrease in PI4P may also contribute to changes in autophagy. A
reduction of PI4P has been postulated to be necessary for lysosome reformation (Rong et al., 2012;
Yu et al., 2010).
The elevation of PI3P, PI(3,5)P2 and PI5P may also have a role in compensating potential mutant
huntingtin-dependent changes in PI or masking of selected PI. Several studies have indicated that
there are polyglutamine-dependent alterations in PI binding of huntingtin protein (Burke et al.,
2013; Kegel et al., 2009a; Kegel et al., 2009b; Kegel et al., 2005). Moreover, wild-type huntingtin
binds phosphoinositide lipids including PI5P and PI(3,5)P2 (Kegel et al., 2009b). Notably, when
assessed using unilamellar vesicles, huntingtin with a polyglutamine expansion bound these lipids
even more tightly than wild-type hungtingtin, potentially reducing the free total levels of these lipids
and impacting their downstream dependent signaling (Kegel-Gleason, 2013). Masking of PI lipids
could negatively and progressively impact the function of proteins involved in autophagosome cargo
recognition and loading, especially those effector proteins dependent on low abundance PI, such as
PI5P and PI(3,5)P2. Additional studies need to be carried out to determine the effectors proteins
(Alfy and/or others) responsible for the action of PIP4Kg modulation, the mechanism of action
behind the high cellular alteration in PI(3,5)P2 as well as the modulation of other PI levels, and the
impact of those changes on mTOR function and autophagy dynamics (Ikonomov et al., 2006;
Jin et al., 2014; Ikonomov et al., 2001). It has not escaped our attention that mHtt-dependent
effects seem to be triggered by aging, which is known to limit the clearance of misfolded proteins
(Komatsu et al., 2007), and deregulate phosphatidylinositide lipid signaling (Igwe and Filla, 1995).
The data presented in this manuscript demonstrates that pharmacological inhibition, or knock-
down of PIP4Kg produce a similar reduction in huntingtin levels, and a concomitant elevation of PI5P
and PI(3,5)P2 and PI3P. These findings open the door to a new disease-modifying approach for this
disorder and validate PIP4Kg as a druggable target. In a recent report, a homozygous mouse knock-
out displayed no growth or behavioral abnormalities (Shim et al., 2016). From the translational point
of view, the development of selective PIP4Kg inhibitors could be extraordinarily useful for other neu-
rodegenerative diseases as well. Alzheimer’s disease and Parkinson’s disease in particular are also
mediated by the accumulation of toxic protein aggregates, whose catabolism by autophagy might
rescue stressed neurons. Starvation increases life spans across species (Speakman and Hambly,
2007) and there are numerous diseases where upregulation of basal autophagy is beneficial
(Hara et al., 2006; Seino et al., 2013). Further, dose response studies are necessary to fully evaluate
the therapeutic potential of PIP4Kg inhibition.
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Materials and methods
Synthesis of NCT-504
General Experimental Procedure: Unless otherwise stated, all reactions were carried out under an
atmosphere of dry argon or nitrogen in dried glassware. Indicated reaction temperatures refer to
those of the reaction bath, while room temperature is noted as ~25˚C. All anhydrous solvents, com-
mercially available starting materials, and reagents were purchased from Aldrich Chemical Co. and
used as received. Chromatography on silica gel was performed using forced flow (liquid) of the indi-
cated solvent system on Biotage KP-Sil pre-packed cartridges and using the Biotage SP-1 automated
chromatography system.
1H spectra were recorded on a Varian Inova 400 MHz spectrometer. Chemical shifts are reported
in ppm with the solvent resonance as the internal standard (DMSO-d6 2.50 ppm, for 1H). Data are
reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br
s = broad singlet, m = multiplet), coupling constants, and number of protons.
Analytical purity analysis and retention times (RT) reported here were performed on an Agilent
LC/MS (Agilent Technologies, Santa Clara, CA). A Phenomenex Luna C18 column (three micron, 3 
75 mm) was used at a temperature of 50˚C. The solvent gradients are mentioned for each com-
pound and consist of a percentage of acetonitrile (containing 0.025% trifluoroacetic acid) in water
(containing 0.05% trifluoroacetic acid). A 4.5 min run time at a flow rate of 1 mL/min was used.
Mass determination was performed using an Agilent 6130 mass spectrometer with electrospray
ionization in the positive mode.
Synthetic scheme to prepare NCT-504:
Scheme 1. Synthetic scheme to prepare NCT-504.
DOI: https://doi.org/10.7554/eLife.29123.023
Synthetic Procedures:
B: A (5-bromo-4-chlorothieno[2,3-d]pyrimidine) was prepared according to WO2012/44993 A1,
2012; Location in patent: Page/Page column 45). A solution of A (1.03 g, 4.13 mmol) in THF (15 ml)
was treated at 0˚C under nitrogen with dropwise addition of isopropylmagnesium chloride (2.48 ml,
4.95 mmol, 2M in THF). The mixture was stirred for 15 min and then a solution of iodine (1.05 g,
4.13 mmol) in THF (10 mL) was added dropwise under nitrogen. The mixture was stirred at 0˚C for
almost 2 hr, quenched with saturated aqueous NH4Cl and then EtOAc was added. The mixture was
stirred, the organic layer was separated, washed with saturated aqueous Na2S2O3, dried with
MgSO4, filtered, concentrated to obtain crude 4-chloro-5-iodothieno[2,3-d]pyrimidine (1.17 g, 3.95
mmol, 96% yield). This appeared to be contaminated with a small amount of B 4-chlorothieno[2,3-d]
pyrimidine (approximately ~5–10% by LC/MS).
1H NMR (400 MHz, DMSO-d6) d 8.96 (s, 1H), 8.46 (s, 1H).
LC/MS Gradient 4% to 100% Acetonitrile (0.05% TFA) over 3.0 min; RT 3.290 min, ESI (M + 1)
+calculated 296.9, found 296.8.
C: A microwave vial filled was charged with 4-chloro-5-iodothieno[2,3-d]pyrimidine B (0.48 g, 1.62
mmol), (3-(methylsulfonyl)phenyl)boronic acid (0.389 g, 1.94 mmol), Pd(PPh3)4 (0.094 g, 0.081 mmol),
sodium carbonate (1.42 ml, 2.83 mmol) followed by dimethoxyethane (8 mL) and water (1 mL). The
mixture was heated in the microwave under ‘high’ settings at 120˚C for 20 min in the microwave.
The mixture was then cooled; celite was added, and concentrated. The adsorbed material was puri-
fied by flash silica gel chromatography with a gradient of 0% to 30% EtOAc in DCM that separated
unreacted starting iodide (~20% recovery) from the required product 4-chloro-5-(3-(methylsulfonyl)
phenyl)thieno[2,3-d]pyrimidine C (0.19 g, 0.59 mmol, 36% yield).
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1H NMR (400 MHz, DMSO-d6) d 9.02 (d, J = 0.4 Hz, 1H), 8.19 (d, J = 0.4 Hz, 1H), 8.08 (td,
J = 1.8, 0.5 Hz, 1H), 8.02 (ddd, J = 7.8, 1.9, 1.1 Hz, 1H), 7.90 (ddd, J = 7.7, 1.7, 1.2 Hz, 1H), 7.77 (td,
J = 7.7, 0.5 Hz, 1H), 3.29 (s, 3H). LC/MS Gradient 4% to 100% Acetonitrile (0.05% TFA) over 3.0 min,
RT 3.014 min, ESI (M + 1)+ calculated 325.0, found 324.9.
NCT-504 4-Chloro-5-(3-(methylsulfonyl)phenyl)thieno[2,3-d]pyrimidine C (0.18 g, 0.55 mmol) with
DME (10 mL) was treated with 1-methyl-1H-tetrazole-5-thiol (0.084 g, 0.720 mmol) and Hunig’s Base
(0.194 mL, 1.11 mmol), and heated at 120˚C for 30 min in a sealed tube. The mixture was cooled,
concentrated, re-dissolved in minimal DCM and the purified by silica gel column chromatography
(5% to 60% EtOAc/DCM) to provide NCT-504 4-((1-methyl-1H-tetrazol-5-yl)thio) 5-(3-(methylsul-
fonyl)phenyl)thieno[2,3-d]pyrimidine (190 mg, 0.470 mmol, 85% yield).
1H NMR (400 MHz, DMSO-d6) d 8.76 (d, J = 0.4 Hz, 1H), 8.23 (td, J = 1.8, 0.5 Hz, 1H), 8.15 (d,
J = 0.4 Hz, 1H), 8.10 (ddd, J = 7.8, 1.9, 1.1 Hz, 1H), 8.02 (ddd, J = 7.7, 1.7, 1.1 Hz, 1H), 7.86 (td,
J = 7.8, 0.6 Hz, 1H), 3.96 (s, 3H), 3.34 (s, 3H).
LC/MS Gradient 4% to 100% Acetonitrile (0.05% TFA) over 3.0 min, RT 3.024 min, ESI (M + 1)+
calculated 405.0, found 405.0.
Enzyme preparation and biochemical assays
Protein from human PIP4K2A (UniGene 138363), PIP4K2B (Unigene 269308) and PIP4K2C (UniGene
6280511) was expressed in pGEX6P (GE Healthcare) and purified from E. coli BL21(DE3). GST fusion
proteins from cell lysates were bound to glutathione sepharose beads (GE Healthcare) and cleaved
in situ with 50U of PreScission protease (GE Healthcare) for 4 hr at 4˚C.
Lipid kinase assays were performed essentially as described previously (Wang et al., 2010;
Clarke et al., 2001). In brief, dried substrate lipid (6 mM PI5P final reaction concentration) was resus-
pended in kinase buffer (50 mM Tris pH 7.4, 10 mM MgCl2, 80 mM KCl, and 2 mM EGTA) and
micelles were formed by sonication for 2 min. Recombinant lipid kinase, preincubated with inhibitor
for 10 min on ice (where required), was added to the micelles and the reaction started by the addi-
tion of 10 mCi [32P]ATP (200 ml final volume), and incubated at 30˚C for 10–60 min (dependent on
isoform). Lipids were extracted using an acidic phase-separation (Bligh and Dyer, 1959) and sepa-
rated by one-dimensional thin layer chromatography (2.8:4:1:0.6 chloroform:methanol:water:ammo-
nia). Radiolabelled PI(4,5)P2 product was detected by autoradiography, extracted from the plate
and Cerenkov radiation was counted in the presence of Ultima Gold XR scintillant (Packard) on a
LS6500 scintillation counter (Beckman Coulter). Specific enzyme activities, under these assay condi-
tions, were calculated as nmoles of PI5P converted into PI(4,5)P2 per minute per mg of purified
recombinant enzyme.
Intrinsic ATPase activities of the enzymes were determined using the Transcreener ADP2 fluores-
cence polarization assay (BellBrook Labs). PIP4Kg (1 mM, [Clarke and Irvine, 2013]) was pre-incu-
bated (10 min on ice) at range of inhibitor concentrations and assayed with ATP substrate (100 mM
ATP, 60 min incubation at 22˚C) in the absence of lipid substrate. Polarization units (mP) were read
using a PHERAstar Plus microplate reader (BMG Labtech). Experimental values were interpolated
from an ADP/ATP utilization standard curve and plotted using nonlinear regression analysis with
Prism 5 (GraphPad).
Measurement of phosphorylated phosphoinositide (PI) levels by HPLC
PI measurements were performed as previously described (Zolov et al., 2012). Briefly, mouse pri-
mary fibroblasts were generated from P1 pups (129P2/OlaHsd  C57BL/6) and were cultured in
DMEM supplemented with 15% FBS and 1X Pen-Strep-Glutamine and human patient fibroblast were
cultured in MEM supplemented with 15% FBS, 1x Pen-Strep and 1x Glutamax in 100 mm dishes to
60–70% confluence. MEF cells and patient fibroblasts were tested using MycoFluor Mycoplasma
Detection Kit (Thermo Scientific Fisher) and were negative for mycoplasma contamination. Cells
were washed with PBS and incubated with inositol labeling medium (containing custom-made inosi-
tol-free DMEM (11964092; Life Technologies), 10 mCi/mL of myo-3H-inositol (GE Healthcare), 10%
dialyzed FBS (26400; Life Technologies), 20 mM Hepes, pH 7.2–7.4, 5 mg/mL transferrin (0030124SA;
Invitrogen), and 5 mg/mL insulin (12585–014; Invitrogen) for 48 hr. For experiments with NCT-504
treatments, cells were treated with indicated concentrations of NCT-504 or DMSO for indicated
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duration before the end of the labeling. Extraction and HPLC measurements were performed as
described (Zolov et al., 2012).
Silencing of PIP4Kg
Primary mouse embryonic fibroblast cells generated from P1 pups (129P2/OlaHsd  C57BL/6) were
infected with MISSION shRNA lentiviral plasmid pLKO.1-puro with shRNA target sequence C
TCCAAGATCAAGGTCAACAA (TRCN0000024702; Sigma) containing 237–257 nucleotides of mouse
PIP4Kg cDNA; MISSION nontarget shRNA lentiviral control vector SHC002 (Sigma) was used as con-
trol. Transduction-ready viral particles were produced by the Vector Core (University of Michigan,
Ann Arbor, MI) with a concentration of 107 transduction units per ml. Mouse primary fibroblast
grown on two 35 mm dishes were treated at an MOI of 5. After overnight incubation, cells were
treated with 2 mg/ml puromycin. After two days of infection, cells from two 35 mm dishes were trans-
ferred to a 100 mm dish and maintained in puromycin containing media for another three days. Cells
were either analyzed by western blot or incubated with inositol labeling medium for 48 hr for PI
measurements. Immunoblots were performed with antibodies against PIP4K2C (17077–1-AP RRID:
AB_2715526, ProteinTech; 1:5000) and GADPH (AM4300 RRID: AB_437392, Thermo Scientific
Fisher; 1:50000).
LC3 measurements in HEK cells
HEK 293T cells grown on 35 mm Dishes till 60–70% confluency were either untreated or treated with
DMSO or NCT-504 with or without 100 nM Bafilomycin for two hours. Cells were lysed and immuno-
blotted with antibodies against LC3A/B (12741 RRID:AB_2617131; Cell Signaling) and a-tubulin (A-
11126 A11126 RRID:AB_221538; Life Technologies). Blots were analyzed using Adobe Photoshop.
HEK293T cells were purchased from ATCC (RRID:CVCL_0063) and were certified authentic and
mycoplasma free.
Htt HTRF assay
Antibodies
The monoclonal antibodies used in the HTRF assay were 2B7 (gift from collaborator) which binds to
the first 17 amino acids of normal and mutant Htt, and MAB2166 (EMD Milipore #MAB2166), which
binds to an Htt epitope (amino acid 181 to 810), and recognizes both normal and mtHtt. The anti-
body 2B7 was conjugated to Tb as a donor, and 2166 was conjugated to d2 as an acceptor (both
were custom labeled by Cisbio). The labeled antibody pairs were diluted in the 1X HTRF assay
buffer: 50 mM NaH2PO4, 400 mM NaF, 0.1%BSA, 0.05% Tween 20. The HTRF assay were performed
at 1536-well plate. For the experiments, cells were seeding (6 mL/well) 24 hr in advanced and culture
at 37˚C 5%CO2 followed by compound addition (23 nL). After incubating with compounds for 24 hr,
cells were lysed by adding 2 mL of 4x lysis buffer (Cisbio Lysis buffer #2), incubated at room tempera-
ture for 2 hr then add labeled antibodies. The labeled antibody pairs were diluted in the 1X HTRF
assay buffer: 50 mM NaH2PO, 400 mM NaF, 0.1%BSA, 0.05% Tween 20. The final reaction is 8 mL/
well. The signal ratio between 665 nm and 615 nm have been calculated as the raw HTRF ratio. The
cell viability was measured by using CellTiter-Glo Luminescent Cell Viability Assay (Promega). The
293A cells were purchased from ThermoFisher Scientific, Cat#R70507, Lot # 1657360. They tested
negative for mycoplasma. They were not sent out for STR since it was first use right after purchase
from company.
Htt exon1 aggregation assay
GFP-Htt-exon1-Q23 (Plasmid #40261)1 and GFP-Htt-exon1-Q74 (Plasmid #40262)1 were purchased
from Addgene (Cambridge, MA) (Narain et al., 1999). Immortalized Atg7+/+ and Atg7-/- MEF cells
were generously provided by Dr. Masaaki Komastu (School of medicine, Niigata University)
(Komatsu et al., 2005). Atg7+/+ and Atg7-/- MEF cells were tested using MycoFluor Mycoplasma
Detection Kit (Thermo Scientific Fisher) and are negative for mycoplasma contamination. They were
validated for the presence and absence, respectively, of Atg7 by the western blot shown in
Figure 3C. These cell lines are not included in the list of commonly misidentified cell lines main-
tained by International Cell Line Authentication Committee were not authenticated further.
HEK293T, Atg7+/+ and Atg7-/- cells grown on coverslips were transfected with either GFP-Htt-
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exon1-Q23 or GFP-Htt-exon1-Q74 using Lipofectamine 2000 (Invitrogen). After 2 hr of transfection,
cells were incubated with DMSO or 2 mM of NCT-504 for 48 hr and fixed. Transfected cells with
mHtt aggregates were quantified (Narain et al., 1999; Komatsu et al., 2005).
HTT quantification in fibroblasts and StHdh cells
Immortalized StHdhQ111 (Coriell-CH00095, RRID:CVCL_M591) cells (Trettel et al., 2000), immortal-
ized wild type (Coriell-GM02153) and HDQ45 (Coriell-GM03868, RRID:CVCL_1H73) HD fibroblasts
((using SV40 large T antigen) (Lu et al., 2013) and non-immortalized HDQ68 (Coriell-GM21757,
RRID:CVCL_1J85) were grown in 15%FBS DMEM with GlutaMax (Life Technologies). For drug treat-
ments, cells were plated overnight until they reached 70% confluence in 12-well plates, drug was
added at the desired concentration for 48 hr. For siRNA treatment cells were nucleofected using
Amaxa at a final concentration of 30 nM and grown in 6-well plates for 72 hr. StHdh cells were
grown in DMEM (Life Technologies) 10% FBS and drug treatment was carried out as described
above. Cell identity was confirmed using STR profiling (GenePrint 10 System from Promega Corp.)
and tested mycoplasma negative (Hoechst staining).
Cells were collected using trypsin, homogenized in RIPA buffer, sonicated and incubated in ice
for 30 min. Supernatant was collected after a 10 min centrifugation and protein concentration was
measured. For western blot analysis 15 mg of each protein sample was loaded in a 4–12% Bis-tris
gel, transferred into a nitrocellulose membrane, blocked with 5% milk and incubated overnight with
anti-Huntingtin antibody MAB5492 (Millipore) for fibroblasts or MAB2166 (Millipore) for StHdhQ111
cells.
Ethical treatment of animals
All vertebrate animal work was approved by the Institutional Animal Use and Care Committee at the
University of Michigan (PRO00007096). Experiments were carefully planned to minimize the number
of animals needed. Pregnant female wild-type, non-transgenic Long Evans rats (Rattus norvegicus)
were housed singly in chambers equipped with environmental enrichment. They were fed ad libitum
a full diet (30% protein, 13% fat, 57% carbohydrate; full information available at www.labdiet.com),
and cared for by the Unit for Laboratory Animal Medicine (ULAM) at the University of Michigan. Vet-
erinary specialists and technicians in ULAM are trained and approved in the care and long-term
maintenance of rodent colonies, in accordance with the NIH-supported Guide for the Care and Use
of Laboratory Animals. All rats were kept in routine housing for as little time as possible prior to
euthanasia and dissection, minimizing any pain and/or discomfort. Pregnant dams were euthanized
by CO2 inhalation at gestation day 20. For each animal, euthanasia was confirmed by bilateral pneu-
mothorax. Euthanasia was fully consistent with the recommendations of the Guidelines on Euthana-
sia of the American Veterinary Medical Association and the University of Michigan Methods of
Euthanasia by Species Guidelines. Following euthanasia, the fetuses were removed in a sterile man-
ner from the uterus and decapitated. Primary cells from these fetuses were dissected and cultured
immediately afterwards.
Rodent primary neuron isolation and culturing
Primary mixed cortical neurons were dissected from these embryos as described previously
(Saudou et al., 1998), and plated in a poly-l-lysine/laminin coated 96 well plate at a density of 5 
105 cells/ml. On day four in vitro, cells were transfected with Dendra2-LC3 with or without GFP-
Beclin using Lipofectamine 2000 (Invitrogen). Thirty minutes post-transfection, neurons were treated
with NCT-504 or DMSO. Optical pulse labeling experiments were performed as previously described
(Tsvetkov et al., 2013; Gupta et al., 2017; Barmada et al., 2014). Briefly, Dendra2-LC3 was photo-
converted 24 hr post-transfection by illuminating each imaging field with a 250 ms pulse of 405 nm
light. Following photoconversion, neurons were longitudinally imaged using a custom-built auto-
mated fluorescence microscopy platform (Arrasate et al., 2004; Barmada et al., 2014;
Barmada et al., 2015). A Nikon Eclipse Ti inverted microscope equipped with a high-NA 20X objec-
tive lens, a PerfectFocus3 system, and an Andor iXon3 897 EMCCD camera were used for image
acquisition. GFP and TRITC images were taken immediately after photoconversion and four more
times within the following 48 hr. Single-cell TRITC intensity values were fitted to a first-order expo-
nential decay curve, generating a half-life value for each individual neuron. Neuronal survival analysis
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was assessed using original software written in Python. Only cells that lived the duration of imaging
were included in the Dendra2-LC3 half-life analysis. Half-life was determined by fitting the TRITC
intensity values at each time point to a first-order exponential function using scripts written in R.
Comparisons between groups to determine statistical significance were accomplished using one-way
ANOVA with Dunnet’s post hoc test and the Kruskal-Wallis test.
Drosophila experiments
Two different Drosophila HTT-expressing strains were used for this study, and N-terminal model
expressing the first 336 amino acids of human HTT with a 128Q expansion (Branco et al., 2008) and
a full length model expressing human HTT with a Q200 expansion (El-Daher et al., 2015). For retinal
expression, we used the GMR-GAL4 driver at 25C and for panneuronal expression, we used the
elav-GAL4 driver. These two drivers as well as the siRNAs targeting dPIP4K were obtained from the
Bloomington Drosophila stock center. The dPIP4K-29 loss of function allele and the K271D kinase
dead (PIP4K-DN) allele were previously described and kindly provided by Dr. Padinjat Raghu
(Gupta et al., 2013).
For the retinal degeneration assay, animals were fixed with 4% formaldehyde in PBS. Heads were
dehydrated in increasing concentrations of ethanol and embedded in paraffin. Ten mm serial sections
were obtained and re-hydrated to PBS. Sections were stained with hematoxylin (SIGMA). Images
were captured using an AxioCam MRc camera (ZEISS) attached to a MICROPHOT-FXA microscope
(Nikon).
Motor performance of animals was assessed as a function of age. For the N-terminal model 15
age-matched virgin females per replica were used. Animals are taped to the bottom of a plastic vial
and the number of animals reaching a height of 9 cm in 15 s is assessed using infrared sensors. Ten
trials are carried out for each day represented. The plotted data corresponds to the average per-
centage of animals reaching 9 cm. Data was analyzed by ANOVA followed by Dunnet’s post hoc
test. For the FL-HTTQ200 a similar procedure was used, the animals were video recorded and data
was processed using a custom designed analysis software (Source code 1), which allowed for calcu-
lating speed.
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